The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review

MRI investigation of immune dysregulation in schizophrenia

(2019) Shiral S. Gangadin et al.   CURRENT OPINION IN PSYCHIATRY

The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder

(2019) Yann Chye et al.   Frontiers in Psychiatry

Cannabidiol reverses attentional bias to cigarette cues in a human experimental model of tobacco withdrawal

(2018) Chandni Hindocha et al.   ADDICTION

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

(2018) Philip McGuire et al.   AMERICAN JOURNAL OF PSYCHIATRY

Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trial

(2018) Jose M. Trigo et al.   PLoS One

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

(2018) Douglas L. Boggs et al.   PSYCHOPHARMACOLOGY

How Many Patients With Schizophrenia Do Not Respond to Antipsychotic Drugs in the Short Term? An Analysis Based on Individual Patient Data From Randomized Controlled Trials

(2018) Myrto T Samara et al.   SCHIZOPHRENIA BULLETIN

Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol

(2018) Christian Makiol et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series

(2017) Regi Schipper et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cannabis-associated psychosis: Neural substrate and clinical impact

(2017) R.M. Murray et al.   NEUROPHARMACOLOGY

Cannabis use and adherence to antipsychotic medication: a systematic review and meta-analysis

(2017) E. Foglia et al.   PSYCHOLOGICAL MEDICINE

Reduced Brain Cannabinoid Receptor Availability in Schizophrenia

(2016) Mohini Ranganathan et al.   BIOLOGICAL PSYCHIATRY

Therapeutic Potential of Cannabinoids in Psychosis

(2016) F. Markus Leweke et al.   BIOLOGICAL PSYCHIATRY

Sativex Associated With Behavioral-Relapse Prevention Strategy as Treatment for Cannabis Dependence

(2016) Jose M. Trigo et al.   Journal of Addiction Medicine

Meta-analysis of the Association Between the Level of Cannabis Use and Risk of Psychosis

(2016) Arianna Marconi et al.   SCHIZOPHRENIA BULLETIN

Endocannabinoid signalling in reward and addiction

(2015) Loren H. Parsons et al.   NATURE REVIEWS NEUROSCIENCE

Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol

(2015) Felipe V. Gomes et al.   SCHIZOPHRENIA RESEARCH

A systematic review of the antipsychotic properties of cannabidiol in humans

(2015) Tabitha A. Iseger et al.   SCHIZOPHRENIA RESEARCH

Acute and Non-acute Effects of Cannabis on Human Memory Function: A Critical Review of Neuroimaging Studies

(2014) Matthijs Bossong et al.   CURRENT PHARMACEUTICAL DESIGN

Role of the endocannabinoid system in brain functions relevant for schizophrenia: An overview of human challenge studies with cannabis or ∆9-tetrahydrocannabinol (THC)

(2014) Matthijs G. Bossong et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal

(2014) David J. Allsop et al.   JAMA Psychiatry

Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings

(2013) Celia J.A. Morgan et al.   ADDICTIVE BEHAVIORS

Increased ventral striatal CB1 receptor binding is related to negative symptoms in drug-free patients with schizophrenia

(2013) Jenny Ceccarini et al.   NEUROIMAGE

Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings

(2013) Albert Batalla et al.   PLoS One

Daily Use, Especially of High-Potency Cannabis, Drives the Earlier Onset of Psychosis in Cannabis Users

(2013) M. Di Forti et al.   SCHIZOPHRENIA BULLETIN

Multiple Functions of Endocannabinoid Signaling in the Brain

(2012) István Katona et al.   Annual Review of Neuroscience

Cannabidiol for the treatment ofcannabiswithdrawal syndrome: a case report

(2012) J. A. S. Crippa et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment

(2012) Amir Englund et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

(2012) F M Leweke et al.   Translational Psychiatry

Cannabis Use and Earlier Onset of Psychosis

(2011) Matthew Large et al.   ARCHIVES OF GENERAL PSYCHIATRY

Effects of endocannabinoid system modulation on cognitive and emotional behavior

(2011) Claudio Zanettini   Frontiers in Behavioral Neuroscience

Cannabis Use and the Course of Schizophrenia: 10-Year Follow-Up After First Hospitalization

(2010) Daniel J. Foti et al.   AMERICAN JOURNAL OF PSYCHIATRY

The environment and schizophrenia

(2010) Jim van Os et al.   NATURE

Quantification of cerebral cannabinoid receptors subtype 1 (CB1) in healthy subjects and schizophrenia by the novel PET radioligand [11C]OMAR

(2010) Dean F. Wong et al.   NEUROIMAGE

Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia

(2010) Matthijs G. Bossong et al.   PROGRESS IN NEUROBIOLOGY

Cannabis use at a young age is associated with psychotic experiences

(2010) C. D. Schubart et al.   PSYCHOLOGICAL MEDICINE

Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)

(2010) Jaime E. C. Hallak et al.   REVISTA BRASILEIRA DE PSIQUIATRIA

Endocannabinoid Signaling and Long-Term Synaptic Plasticity

(2009) Boris D. Heifets et al.   Annual Review of Physiology

Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation

(2009) Guy A. Cabral et al.   EXPERT REVIEWS IN MOLECULAR MEDICINE

Endocannabinoid-Mediated Control of Synaptic Transmission

(2009) Masanobu Kano et al.   PHYSIOLOGICAL REVIEWS

Cytokines and schizophrenia: Microglia hypothesis of schizophrenia

(2009) Akira Monji et al.   PSYCHIATRY AND CLINICAL NEUROSCIENCES

Substance Use Disorders in Schizophrenia--Clinical Implications of Comorbidity

(2009) N. D. Volkow   SCHIZOPHRENIA BULLETIN

Schizophrenia, “just the facts” 4. Clinical features and conceptualization

(2009) Rajiv Tandon et al.   SCHIZOPHRENIA RESEARCH

The Therapeutic Potential of the Endocannabinoid System for the Development of a Novel Class of Antidepressants

(2009) Matthew N. Hill et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond

(2008) Roger G. Pertwee   ADDICTION BIOLOGY

Cannabis and psychiatric disorders: it is not only addiction

(2008) F. Markus Leweke et al.   ADDICTION BIOLOGY

Neurobiological mechanisms of cannabinoid addiction

(2008) L. Fattore et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

Psychiatric Comorbidities and Schizophrenia

(2008) P. F. Buckley et al.   SCHIZOPHRENIA BULLETIN